Your cart is empty
Continue Shopping
Dual action for appetite and weight
from €64.95
Tirzepatide (research code LY3298176) was the first compound to engage two incretin receptors at once: GIP and GLP-1. Both are gut hormones released after eating, and together they sit at the heart of how the body regulates appetite, blood sugar and energy storage. That dual action places tirzepatide neatly between semaglutide, which works on GLP-1 alone, and retatrutide, which adds the glucagon receptor as a third. Veyron offers it in five strengths so a project can be sized precisely.
| Form | Lyophilised powder in a sealed vial |
|---|---|
| Strengths | 10 · 20 · 30 · 40 · 60 mg |
| Molecular formula | C225H348N48O68 |
| Molecular weight | ≈ 4,813 Da |
| Purity | ≥ 99% (HPLC) |
| Storage | Refrigerated, away from light and moisture |
| Bundle options | Bacteriostatic water, insulin syringes (0.5 or 1 ml), alcohol wipes |
Every Veyron batch is checked by HPLC before it is released and ships in a sealed vial, so what arrives matches what is on the label.
Veyron products are sold for research purposes only. They are not intended for human consumption, nor to diagnose, treat, cure or prevent any condition.
No. Start with what you want to achieve. Every collection and every product page explains the names for you.
Every batch is tested for purity by HPLC before it is released, and the certificate of analysis is available on request.
Orders placed on a working day before 14:00 ship the same day, in neutral packaging. You receive a tracking link by email as soon as it leaves.
from €39.95
No. All Veyron products are sold exclusively for research purposes and are not intended to diagnose, treat or prevent any condition.